Sanofi and GlaxoSmithKline's new crown vaccine booster has good preliminary data

$Sanofi(SNY.US)$ $GlaxoSmithKline(GSK.US)$ Sanofi (SNY.US) and GlaxoSmithKline (GSK.US) announced good preliminary data for the booster dose of the new crown vaccine. It is reported that the preliminary results of the clinical trial of VAT0002 show that no matter what the main vaccine is received, for all age groups tested, a single booster dose will increase neutralizing antibodies by 9 to 43 times. In the study, the enhanced needle is well tolerated, and it is expected that more test data will be available in the first half of 2022.

Article excerpted from the US Stock Research Agency